[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2010009416A - Compuestos heterociclicos como inhibidores de cxcr2. - Google Patents

Compuestos heterociclicos como inhibidores de cxcr2.

Info

Publication number
MX2010009416A
MX2010009416A MX2010009416A MX2010009416A MX2010009416A MX 2010009416 A MX2010009416 A MX 2010009416A MX 2010009416 A MX2010009416 A MX 2010009416A MX 2010009416 A MX2010009416 A MX 2010009416A MX 2010009416 A MX2010009416 A MX 2010009416A
Authority
MX
Mexico
Prior art keywords
cxcr2
inhibitors
heterocyclic compounds
compounds
heterocyclic
Prior art date
Application number
MX2010009416A
Other languages
English (en)
Inventor
Simon James Watson
Carsten Spanka
Paul Oakley
Neil John Press
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010009416A publication Critical patent/MX2010009416A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a los compuestos de la fórmula (I): (ver fórmula (I)) en donde R1, R2, X, Y y Z son como se definen en la memoria descriptiva.
MX2010009416A 2008-02-26 2009-02-25 Compuestos heterociclicos como inhibidores de cxcr2. MX2010009416A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08151952 2008-02-26
PCT/EP2009/052211 WO2009106539A1 (en) 2008-02-26 2009-02-25 Heterocyclic compounds as inhibitors of cxcr2

Publications (1)

Publication Number Publication Date
MX2010009416A true MX2010009416A (es) 2010-09-24

Family

ID=39271993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009416A MX2010009416A (es) 2008-02-26 2009-02-25 Compuestos heterociclicos como inhibidores de cxcr2.

Country Status (11)

Country Link
US (1) US20110009429A1 (es)
EP (1) EP2257552A1 (es)
JP (1) JP2011513273A (es)
KR (1) KR20100133385A (es)
CN (1) CN101959889A (es)
AU (1) AU2009218515A1 (es)
BR (1) BRPI0908529A2 (es)
CA (1) CA2714500A1 (es)
EA (1) EA201001359A1 (es)
MX (1) MX2010009416A (es)
WO (1) WO2009106539A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012015292A (es) 2010-06-24 2013-05-30 Gilead Sciences Inc Pirazolo[1, 5]pirimidinas en la forma de agentes antivirales.
JP2013538838A (ja) * 2010-09-27 2013-10-17 プロクシマゲン リミテッド ７−ヒドロキシ−ピラゾロ［１，５−ａ］ピリミジン化合物およびｃｃｒ２レセプターアンタゴニストとしてのその使用
ES2647486T3 (es) 2011-12-22 2017-12-21 Gilead Sciences, Inc. Pirazolo[1,5-a]pirimidinas como agentes antivirales
AU2013249280B2 (en) 2012-04-17 2017-10-12 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
JP6527851B2 (ja) 2013-03-12 2019-06-05 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素を阻害する方法
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
EP2970309A4 (en) * 2013-03-14 2016-11-09 Celtaxsys Inc INHIBITORS OF LEUCOTRIENE A4 HYDROLASE
PL236355B1 (pl) 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
EP3377488B1 (en) 2015-11-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
PT3394033T (pt) 2015-12-22 2021-01-29 Incyte Corp Compostos heterocíclicos como imunomoduladores
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
JP7042812B2 (ja) 2016-06-20 2022-03-28 ノバルティス アーゲー トリアゾロピリミジン化合物の結晶形態
CN109890819B (zh) 2016-06-20 2022-11-22 因赛特公司 作为免疫调节剂的杂环化合物
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3047980A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
CR20190318A (es) 2016-12-22 2019-10-21 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MX2020004756A (es) 2017-11-16 2020-08-20 Novartis Ag Terapias de combinacion.
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
PE20211911A1 (es) 2018-03-30 2021-09-28 Incyte Corp Compuestos heterociclicos como inmunomoduladores
EP3790877B1 (en) 2018-05-11 2023-03-01 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
JP7386815B2 (ja) 2018-05-31 2023-11-27 セルタクシー、エルエルシー 呼吸器疾患患者の肺増悪を軽減する方法
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JP2022514315A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
AU2020222345B2 (en) 2019-02-15 2022-11-17 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021009764A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
US11401279B2 (en) 2019-09-30 2022-08-02 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
KR20220101664A (ko) 2019-11-11 2022-07-19 인사이트 코포레이션 Pd-1/pd-l1 억제제의 염 및 결정질 형태
TW202135858A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 抗ＴＧＦβ抗體和檢查點抑制劑用於治療增殖性疾病之用途
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
KR20230117573A (ko) 2020-11-06 2023-08-08 인사이트 코포레이션 Pd-1 및 pd-l1 억제제, 및 이의 염 및 결정형의 제조 방법
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
KR101088922B1 (ko) * 2002-09-04 2011-12-01 파마코페이아, 엘엘씨. 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
EP1618108A2 (en) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists

Also Published As

Publication number Publication date
KR20100133385A (ko) 2010-12-21
AU2009218515A1 (en) 2009-09-03
EP2257552A1 (en) 2010-12-08
CA2714500A1 (en) 2009-09-03
CN101959889A (zh) 2011-01-26
JP2011513273A (ja) 2011-04-28
BRPI0908529A2 (pt) 2015-09-29
WO2009106539A1 (en) 2009-09-03
EA201001359A1 (ru) 2011-04-29
US20110009429A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
CY1119515T1 (el) Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης
MX2009008264A (es) Compuestos espiro heterociclicos.
NZ597517A (en) 5-fluoropyrimidinone derivatives
TW200716636A (en) Heterocyclic spiro-compounds
TW200611898A (en) Organic compounds
MY153880A (en) Proline derivatives as cathepsin inhibitors
TW200716105A (en) Imidazole compounds
TW200616623A (en) Organic compounds
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
EA201200119A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
SG171593A1 (en) Inhibitors of c-fms kinase
TW200716634A (en) Heterocyclic spiro-compounds
PL2126020T3 (pl) Hydrofobowo modyfikowane polialkilenoiminy jako inhibitory przenoszenia barwnika
MX2009005934A (es) Compuestos organicos.
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
TW200608978A (en) Organic compounds
MX2012008141A (es) Compuestos y metodos.
NZ597483A (en) N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
HK1141790A1 (es)
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
CO6551705A2 (es) Derivados de 3.4.4a.10b- tetrahidro-1h-tiopirano-[4.3-c]- isoquinolina
MX2009004947A (es) Arilsulfonil-pirrolidinas como inhibidores 5-hidroxitriptaminas6 (5-ht6).
TW200611897A (en) Organic compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal